Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1999-02

AUTHORS

PJ van Horssen, YVJM van Oosterhout, S Evers, HHJ Backus, MGCT van Oijen, R Bongaerts, T de Witte, FW Preijers

ABSTRACT

Despite the strong in vitro activity of some immunotoxins (ITs), clinical application did not result in complete cure. The outcome of therapy may be improved by combining ITs with IT-cytotoxicity enhancing agents. We studied the effect of various agents that influence the intracellular routing of ITs on the activity of the anti-B cell IT CD22-recombinant (rec) ricin A. In protein synthesis inhibition assays the carboxylic ionophores monensin and nigericin enhanced the activity of the IT 117- and 382-fold, respectively, against the cell line Daudi, and 81- and 318-fold, respectively, against the cell line Ramos. IT activity to Daudi and Ramos was enhanced to a lesser extent by the lysosomotropic amines chloroquine (14- and 11-fold, respectively) and NH4Cl (nine- and 10-fold, respectively). However, the combination of NH4Cl and chloroquine induced more than an additive effect (145- and 107-fold, respectively). Cytotoxicity was not influenced by brefeldin A, all-trans retinoic acid (ATRA), verapamil and perhexiline maleate. Bacitracin enhanced the IT cytotoxicity in contrast to the other protease inhibitors aprotinin, leupeptin and soybean trypsin inhibitor, albeit enhancement was weak (two-fold). The enhancers exerted only a negligible effect on bone marrow progenitor cells. We recently developed a flow cytometric cytotoxicity assay in which cell elimination can be assessed. In order to detect enhancement in this assay, we used 5 x 10(-11) M IT (approximately the 50% protein synthesis inhibiting dose (ID50)). This concentration killed 41% of the Daudi cells and 42% of the Ramos cells. In the presence of 10 nM monensin the IT killed 74% and 99% and in the presence of 10 nM nigericin 96% and 99% of the Daudi and Ramos cells, respectively. At 10(-8) M, CD22-rec ricin A eliminated malignant cells originating from three patients with B-CLL (0.42 log) and two with B-ALL (0.19 log) patients. Cytotoxicity to malignant cells was enhanced by NH4Cl, chloroquine, monensin and nigericin. The combination of NH4Cl and chloroquine enhanced the activity most effectively (up to 2.06 log). To determine the applicability of the IT in combination with enhancers in vivo we investigated the effect of human serum. Human serum inhibited IT activity which could not be restored by monensin and nigericin because of complete inhibition of these enhancers by serum. In contrast, chloroquine partially restored the activity of CD22-rec ricin A in the presence of human serum. We conclude that monensin, nigericin and the combination of NH4Cl and chloroquine can be used instead of NH4Cl to potentiate CD22-rec ricin A activity in purging autologous bone marrow transplants contaminated with malignant B cells. Chloroquine might be a promising enhancer of CD22-rec ricin A for treating patients in vivo. More... »

PAGES

241

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.leu.2401262

DOI

http://dx.doi.org/10.1038/sj.leu.2401262

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052748680

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10025898


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Differentiation, B-Lymphocyte", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Physiological Phenomena", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Purging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Burkitt Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium Channel Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Adhesion Molecules", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lectins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Lymphocytic, Chronic, B-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoproliferative Disorders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Synthesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ricin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sialic Acid Binding Ig-like Lectin 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Horssen", 
        "givenName": "PJ", 
        "id": "sg:person.0740323644.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740323644.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Oosterhout", 
        "givenName": "YVJM", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Evers", 
        "givenName": "S", 
        "id": "sg:person.01155051441.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155051441.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Backus", 
        "givenName": "HHJ", 
        "id": "sg:person.011214077004.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011214077004.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Oijen", 
        "givenName": "MGCT", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bongaerts", 
        "givenName": "R", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Department of Hematology, University Hospital St Radboud, Nijmegen, The Netherlands", 
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Witte", 
        "givenName": "T", 
        "id": "sg:person.015730551677.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015730551677.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Preijers", 
        "givenName": "FW", 
        "id": "sg:person.01141450140.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141450140.79"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3109/10428199309148526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003989055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0005-2736(92)90291-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012069472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0005-2736(92)90291-s", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012069472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.2910560413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013267082"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015450416", 
          "https://doi.org/10.1007/bf00199994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00199994", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015450416", 
          "https://doi.org/10.1007/bf00199994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1432-1033.1975.tb21001.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026573013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-6632.1987.tb45800.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027939455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.2910420527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030164040"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-5793(93)81337-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033571048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0014-4827(80)90270-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042454441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.immunol.14.1.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044390423"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.4.292", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1987.5.4.641", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079821127"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1999-02", 
    "datePublishedReg": "1999-02-01", 
    "description": "Despite the strong in vitro activity of some immunotoxins (ITs), clinical application did not result in complete cure. The outcome of therapy may be improved by combining ITs with IT-cytotoxicity enhancing agents. We studied the effect of various agents that influence the intracellular routing of ITs on the activity of the anti-B cell IT CD22-recombinant (rec) ricin A. In protein synthesis inhibition assays the carboxylic ionophores monensin and nigericin enhanced the activity of the IT 117- and 382-fold, respectively, against the cell line Daudi, and 81- and 318-fold, respectively, against the cell line Ramos. IT activity to Daudi and Ramos was enhanced to a lesser extent by the lysosomotropic amines chloroquine (14- and 11-fold, respectively) and NH4Cl (nine- and 10-fold, respectively). However, the combination of NH4Cl and chloroquine induced more than an additive effect (145- and 107-fold, respectively). Cytotoxicity was not influenced by brefeldin A, all-trans retinoic acid (ATRA), verapamil and perhexiline maleate. Bacitracin enhanced the IT cytotoxicity in contrast to the other protease inhibitors aprotinin, leupeptin and soybean trypsin inhibitor, albeit enhancement was weak (two-fold). The enhancers exerted only a negligible effect on bone marrow progenitor cells. We recently developed a flow cytometric cytotoxicity assay in which cell elimination can be assessed. In order to detect enhancement in this assay, we used 5 x 10(-11) M IT (approximately the 50% protein synthesis inhibiting dose (ID50)). This concentration killed 41% of the Daudi cells and 42% of the Ramos cells. In the presence of 10 nM monensin the IT killed 74% and 99% and in the presence of 10 nM nigericin 96% and 99% of the Daudi and Ramos cells, respectively. At 10(-8) M, CD22-rec ricin A eliminated malignant cells originating from three patients with B-CLL (0.42 log) and two with B-ALL (0.19 log) patients. Cytotoxicity to malignant cells was enhanced by NH4Cl, chloroquine, monensin and nigericin. The combination of NH4Cl and chloroquine enhanced the activity most effectively (up to 2.06 log). To determine the applicability of the IT in combination with enhancers in vivo we investigated the effect of human serum. Human serum inhibited IT activity which could not be restored by monensin and nigericin because of complete inhibition of these enhancers by serum. In contrast, chloroquine partially restored the activity of CD22-rec ricin A in the presence of human serum. We conclude that monensin, nigericin and the combination of NH4Cl and chloroquine can be used instead of NH4Cl to potentiate CD22-rec ricin A activity in purging autologous bone marrow transplants contaminated with malignant B cells. Chloroquine might be a promising enhancer of CD22-rec ricin A for treating patients in vivo.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.leu.2401262", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1097065", 
        "issn": [
          "0887-6924", 
          "1476-5551"
        ], 
        "name": "Leukemia", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "name": "Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells", 
    "pagination": "241", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fb421ccec012eb992e1030dc4faa0a12dc96bffc2eaa4720737449d15a9422e4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10025898"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8704895"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.leu.2401262"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052748680"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.leu.2401262", 
      "https://app.dimensions.ai/details/publication/pub.1052748680"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000360_0000000360/records_118321_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/2401262"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.leu.2401262'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      21 PREDICATES      59 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.leu.2401262 schema:about N01b4b0912e334456a05e4de1ab289409
2 N1559d748dff7482793804eb3d15ac780
3 N35a61c14947c45d486f44e9391fd245d
4 N45a8929d0193444582e24134f1178f61
5 N70b512cf33bd4c7bb32d0b49a76e91bc
6 N73f62959fc1b4d2499727c9488318e39
7 N765d7e67b14d40c2aaf7726ec8a408cb
8 N7c057701301a45028294f13f5242d532
9 N8c6e50709d7e4ec5afcc418336928dc7
10 N905b4388418a4939979c1ab35e1ab86d
11 Na23e62851d06497eaa482b36535ea6bf
12 Nabe50be7ea994868a208d7c7e9afc886
13 Nbbc8042d92dc47a2bc7745977e931da6
14 Nc0044a805db140df805fb79658426266
15 Nc233f733688a420ab722ad7b15042ead
16 Ncd16842f0762464aabea37d4481ca7a9
17 Nd4f76c5dc39a464d9a00e227de680dd0
18 Ndae597c982094e4295a3405d160df11f
19 anzsrc-for:11
20 anzsrc-for:1103
21 schema:author Nf30e4eb56bc94df39bd8c9647e8459f7
22 schema:citation sg:pub.10.1007/bf00199994
23 https://doi.org/10.1002/ijc.2910420527
24 https://doi.org/10.1002/ijc.2910560413
25 https://doi.org/10.1016/0005-2736(92)90291-s
26 https://doi.org/10.1016/0014-4827(80)90270-0
27 https://doi.org/10.1016/0014-5793(93)81337-y
28 https://doi.org/10.1093/jnci/85.4.292
29 https://doi.org/10.1111/j.1432-1033.1975.tb21001.x
30 https://doi.org/10.1111/j.1749-6632.1987.tb45800.x
31 https://doi.org/10.1146/annurev.immunol.14.1.49
32 https://doi.org/10.1200/jco.1987.5.4.641
33 https://doi.org/10.3109/10428199309148526
34 schema:datePublished 1999-02
35 schema:datePublishedReg 1999-02-01
36 schema:description Despite the strong in vitro activity of some immunotoxins (ITs), clinical application did not result in complete cure. The outcome of therapy may be improved by combining ITs with IT-cytotoxicity enhancing agents. We studied the effect of various agents that influence the intracellular routing of ITs on the activity of the anti-B cell IT CD22-recombinant (rec) ricin A. In protein synthesis inhibition assays the carboxylic ionophores monensin and nigericin enhanced the activity of the IT 117- and 382-fold, respectively, against the cell line Daudi, and 81- and 318-fold, respectively, against the cell line Ramos. IT activity to Daudi and Ramos was enhanced to a lesser extent by the lysosomotropic amines chloroquine (14- and 11-fold, respectively) and NH4Cl (nine- and 10-fold, respectively). However, the combination of NH4Cl and chloroquine induced more than an additive effect (145- and 107-fold, respectively). Cytotoxicity was not influenced by brefeldin A, all-trans retinoic acid (ATRA), verapamil and perhexiline maleate. Bacitracin enhanced the IT cytotoxicity in contrast to the other protease inhibitors aprotinin, leupeptin and soybean trypsin inhibitor, albeit enhancement was weak (two-fold). The enhancers exerted only a negligible effect on bone marrow progenitor cells. We recently developed a flow cytometric cytotoxicity assay in which cell elimination can be assessed. In order to detect enhancement in this assay, we used 5 x 10(-11) M IT (approximately the 50% protein synthesis inhibiting dose (ID50)). This concentration killed 41% of the Daudi cells and 42% of the Ramos cells. In the presence of 10 nM monensin the IT killed 74% and 99% and in the presence of 10 nM nigericin 96% and 99% of the Daudi and Ramos cells, respectively. At 10(-8) M, CD22-rec ricin A eliminated malignant cells originating from three patients with B-CLL (0.42 log) and two with B-ALL (0.19 log) patients. Cytotoxicity to malignant cells was enhanced by NH4Cl, chloroquine, monensin and nigericin. The combination of NH4Cl and chloroquine enhanced the activity most effectively (up to 2.06 log). To determine the applicability of the IT in combination with enhancers in vivo we investigated the effect of human serum. Human serum inhibited IT activity which could not be restored by monensin and nigericin because of complete inhibition of these enhancers by serum. In contrast, chloroquine partially restored the activity of CD22-rec ricin A in the presence of human serum. We conclude that monensin, nigericin and the combination of NH4Cl and chloroquine can be used instead of NH4Cl to potentiate CD22-rec ricin A activity in purging autologous bone marrow transplants contaminated with malignant B cells. Chloroquine might be a promising enhancer of CD22-rec ricin A for treating patients in vivo.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N185df023b458421d8f3c0bbce665dc90
41 Nd81af2eb82814587a6f9911d637dd698
42 sg:journal.1097065
43 schema:name Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells
44 schema:pagination 241
45 schema:productId N223fba89f3e34b09a4b1942744f33d32
46 N37b58aad873d46ed90e4669d41e04823
47 N5828efd8f8a24c62bd86a250b7838f5b
48 Nec79383f0f6741c1ae83f719ae88eb63
49 Nef4b211a26b443529a7a07adada2d8f6
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052748680
51 https://doi.org/10.1038/sj.leu.2401262
52 schema:sdDatePublished 2019-04-11T12:05
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N3e1a26240d544be0952cd7af2e767d34
55 schema:url https://www.nature.com/articles/2401262
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N01b4b0912e334456a05e4de1ab289409 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Cell Line
61 rdf:type schema:DefinedTerm
62 N1559d748dff7482793804eb3d15ac780 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Tumor Cells, Cultured
64 rdf:type schema:DefinedTerm
65 N185df023b458421d8f3c0bbce665dc90 schema:volumeNumber 13
66 rdf:type schema:PublicationVolume
67 N1cfa1ad14bb84f8095f953265f807a07 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
68 schema:familyName Bongaerts
69 schema:givenName R
70 rdf:type schema:Person
71 N223fba89f3e34b09a4b1942744f33d32 schema:name readcube_id
72 schema:value fb421ccec012eb992e1030dc4faa0a12dc96bffc2eaa4720737449d15a9422e4
73 rdf:type schema:PropertyValue
74 N2c6e09af4cc541d8babdb1b73ff472d4 rdf:first sg:person.015730551677.08
75 rdf:rest Na52c844a4c43414783ceb0dae681a599
76 N35a61c14947c45d486f44e9391fd245d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Protein Synthesis Inhibitors
78 rdf:type schema:DefinedTerm
79 N37b58aad873d46ed90e4669d41e04823 schema:name nlm_unique_id
80 schema:value 8704895
81 rdf:type schema:PropertyValue
82 N3e1a26240d544be0952cd7af2e767d34 schema:name Springer Nature - SN SciGraph project
83 rdf:type schema:Organization
84 N3e83cc7360b84bb98eaf635dfa715fe4 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
85 schema:familyName van Oosterhout
86 schema:givenName YVJM
87 rdf:type schema:Person
88 N42d7b06f16a34d7590ed18d36e3da66a rdf:first sg:person.01155051441.94
89 rdf:rest N742b9d6aa96e4198b951b50ad441bdbe
90 N45a8929d0193444582e24134f1178f61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Leukemia, Lymphocytic, Chronic, B-Cell
92 rdf:type schema:DefinedTerm
93 N5828efd8f8a24c62bd86a250b7838f5b schema:name pubmed_id
94 schema:value 10025898
95 rdf:type schema:PropertyValue
96 N5f658aacb4484eda8f3d6fe9995e15b3 rdf:first N1cfa1ad14bb84f8095f953265f807a07
97 rdf:rest N2c6e09af4cc541d8babdb1b73ff472d4
98 N65f5cd48afd04d77bb0bd34374a887a7 rdf:first N3e83cc7360b84bb98eaf635dfa715fe4
99 rdf:rest N42d7b06f16a34d7590ed18d36e3da66a
100 N70b512cf33bd4c7bb32d0b49a76e91bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Cell Adhesion Molecules
102 rdf:type schema:DefinedTerm
103 N73f62959fc1b4d2499727c9488318e39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Bone Marrow Purging
105 rdf:type schema:DefinedTerm
106 N742b9d6aa96e4198b951b50ad441bdbe rdf:first sg:person.011214077004.08
107 rdf:rest Nd338ad0157954595ae217c39797faf7f
108 N765d7e67b14d40c2aaf7726ec8a408cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Cell Survival
110 rdf:type schema:DefinedTerm
111 N7c057701301a45028294f13f5242d532 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Humans
113 rdf:type schema:DefinedTerm
114 N835fb5913fa94d3b9e4feb97ab992f4a schema:affiliation https://www.grid.ac/institutes/grid.10417.33
115 schema:familyName van Oijen
116 schema:givenName MGCT
117 rdf:type schema:Person
118 N8c6e50709d7e4ec5afcc418336928dc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Antigens, CD
120 rdf:type schema:DefinedTerm
121 N905b4388418a4939979c1ab35e1ab86d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Lymphoproliferative Disorders
123 rdf:type schema:DefinedTerm
124 Na23e62851d06497eaa482b36535ea6bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Burkitt Lymphoma
126 rdf:type schema:DefinedTerm
127 Na52c844a4c43414783ceb0dae681a599 rdf:first sg:person.01141450140.79
128 rdf:rest rdf:nil
129 Nabe50be7ea994868a208d7c7e9afc886 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Lectins
131 rdf:type schema:DefinedTerm
132 Nbbc8042d92dc47a2bc7745977e931da6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Sialic Acid Binding Ig-like Lectin 2
134 rdf:type schema:DefinedTerm
135 Nc0044a805db140df805fb79658426266 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Recombinant Proteins
137 rdf:type schema:DefinedTerm
138 Nc233f733688a420ab722ad7b15042ead schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Blood Physiological Phenomena
140 rdf:type schema:DefinedTerm
141 Ncd16842f0762464aabea37d4481ca7a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Calcium Channel Blockers
143 rdf:type schema:DefinedTerm
144 Nd338ad0157954595ae217c39797faf7f rdf:first N835fb5913fa94d3b9e4feb97ab992f4a
145 rdf:rest N5f658aacb4484eda8f3d6fe9995e15b3
146 Nd4f76c5dc39a464d9a00e227de680dd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antigens, Differentiation, B-Lymphocyte
148 rdf:type schema:DefinedTerm
149 Nd81af2eb82814587a6f9911d637dd698 schema:issueNumber 2
150 rdf:type schema:PublicationIssue
151 Ndae597c982094e4295a3405d160df11f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Ricin
153 rdf:type schema:DefinedTerm
154 Nec79383f0f6741c1ae83f719ae88eb63 schema:name dimensions_id
155 schema:value pub.1052748680
156 rdf:type schema:PropertyValue
157 Nef4b211a26b443529a7a07adada2d8f6 schema:name doi
158 schema:value 10.1038/sj.leu.2401262
159 rdf:type schema:PropertyValue
160 Nf30e4eb56bc94df39bd8c9647e8459f7 rdf:first sg:person.0740323644.24
161 rdf:rest N65f5cd48afd04d77bb0bd34374a887a7
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
166 schema:name Clinical Sciences
167 rdf:type schema:DefinedTerm
168 sg:journal.1097065 schema:issn 0887-6924
169 1476-5551
170 schema:name Leukemia
171 rdf:type schema:Periodical
172 sg:person.011214077004.08 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
173 schema:familyName Backus
174 schema:givenName HHJ
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011214077004.08
176 rdf:type schema:Person
177 sg:person.01141450140.79 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
178 schema:familyName Preijers
179 schema:givenName FW
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141450140.79
181 rdf:type schema:Person
182 sg:person.01155051441.94 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
183 schema:familyName Evers
184 schema:givenName S
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155051441.94
186 rdf:type schema:Person
187 sg:person.015730551677.08 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
188 schema:familyName de Witte
189 schema:givenName T
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015730551677.08
191 rdf:type schema:Person
192 sg:person.0740323644.24 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
193 schema:familyName van Horssen
194 schema:givenName PJ
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740323644.24
196 rdf:type schema:Person
197 sg:pub.10.1007/bf00199994 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015450416
198 https://doi.org/10.1007/bf00199994
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1002/ijc.2910420527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030164040
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1002/ijc.2910560413 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013267082
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/0005-2736(92)90291-s schema:sameAs https://app.dimensions.ai/details/publication/pub.1012069472
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/0014-4827(80)90270-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042454441
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/0014-5793(93)81337-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1033571048
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1093/jnci/85.4.292 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818418
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1111/j.1432-1033.1975.tb21001.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026573013
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1111/j.1749-6632.1987.tb45800.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027939455
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1146/annurev.immunol.14.1.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044390423
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1200/jco.1987.5.4.641 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079821127
219 rdf:type schema:CreativeWork
220 https://doi.org/10.3109/10428199309148526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003989055
221 rdf:type schema:CreativeWork
222 https://www.grid.ac/institutes/grid.10417.33 schema:alternateName Radboud University Nijmegen Medical Centre
223 schema:name Central Hematology Laboratory, University Hospital St Radboud, Nijmegen, The Netherlands
224 Department of Hematology, University Hospital St Radboud, Nijmegen, The Netherlands
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...